SOURCE: The Bedford Report

The Bedford Report

May 02, 2011 08:16 ET

Oncology Drug Makers Positioned for Long Term Growth

The Bedford Report Provides Analyst Research on Spectrum Pharmaceuticals & Allos Therapeutics

NEW YORK, NY--(Marketwire - May 2, 2011) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and Allos Therapeutics, Inc. (NASDAQ: ALTH). Access to the full company reports can be found at:

IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.

The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

Spectrum Pharmaceuticals operates as a commercial-stage biotechnology company with a primary focus in oncology and hematology. Its core product "Fusilev" is used to treat the side effects of the chemotherapy drug methotrexate. The company recently announced that it expects its product sales to be around $40 million in the first quarter -- almost six times its total from a year ago.

Allos launched Folotyn in January 2010 to treat patients with a relapsed form of the cancer. Allos said its fourth-quarter net loss narrowed to $18.1 million, or 17 cents per share.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information